[Articles] Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial

Data Readoutpositivecabotegravir–rilpivirineTLDPositive

AI Analysis

Summary

LATA trial demonstrates LAI cabotegravir–rilpivirine was superior to TLD for maintaining virological suppression in adolescents living with HIV in sub-Saharan Africa over 96 weeks, with no new safety concerns, supporting its use as a maintenance treatment option in this population.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

LAI cabotegravir–rilpivirine was superior to TLD for maintaining virological suppression in adolescents with HIV with virological suppression, with no new safety concerns observed

Importance:7/10

Sentiment:

0.80

HIVadolescentslong-acting injectablemaintenance therapysub-Saharan Africanon-inferiority trialvirological suppression

Related Companies

$OPTN

Read the original article

Published by The Lancet on September 17, 2026 10:30 PM

Read Original